MONTREAL, QC and EDMONTON, AB, July 7, 2021 -- Montrium, a leader in cloud-based software solutions for life science organizations, today announces that Entos Pharmaceuticals (Entos), a trailblazer in the development of genetic medicine, has selected eTMF Connect and Quality Connect to serve as its official in-house software for managing clinical operations and supporting its continued development of innovative pharmaceutical products.

Primarily focusing on the creation of next-generation genetic therapies utilizing their Fusogenix nucleic acid delivery platform, Entos has been rapidly growing both its business operations and its product portfolio. With an increasing number of staff located across North America, Entos realized that it would be necessary to implement a digital, centralized system to manage essential clinical trial documentation and facilitate crucial clinical research projects.

When searching for a software provider, Entos was delighted by Montrium’s convenient solutions, which enabled them to swiftly begin honing their quality documentation processes.

“We liked the off-the-shelf product that Montrium was able to offer,” said Kevin James, Quality Coordinator and Business Development Specialist at Entos.

He also emphasized how comprehensive Montrium’s offerings were, stating that “Montrium was one of the very few companies that was able to offer both an eTMF platform and a suite of quality support management for documentation and training.”

The partnership between Entos and Montrium represents the massive potential of Canadian companies in driving clinical innovation. Working with Montrium’s eTMF Connect and Quality Connect software, Entos was able to implement rigorous quality processes while also progressing with their development of a promising COVID-19 vaccine, which is now being tested in a phase 1 clinical trial in Halifax, Nova Scotia.

“Montrium was able to help us accelerate our quality management documentation systems as we have been rapidly advancing our COVID-19 vaccine program in Canada,” stated Kevin James.
“We are proud to be partnering with a fellow Canadian company in their journey to develop groundbreaking therapies by ensuring that they have the best tools for managing essential trial documentation and meeting quality standards. We are excited to see how eTMF Connect and Quality Connect will continue to help Entos lead the pharmaceutical industry,” said Michael Pupil, Head of Sales at Montrium.

About Montrium

Founded in 2005, Montrium is one of the leading providers of cloud-based collaborative content management software to the life sciences industry. With experience in serving over 200 life science customers in 20+countries, Montrium is committed to delivering an unparalleled customer experience to emerging growth organizations as a true technology partner. Montrium has offices in Montreal, Canada, and Brussels, Belgium.

About Entos Pharmaceuticals, Inc.

Entos develops next generation nucleic acid-based therapies using its proprietary Fusogenix drug delivery system. Fusogenix is a proteo-lipid vehicle (PLV) formulation that uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology applies a wide range of therapeutic types, including gene therapy, mRNA, miRNA, RNAi, CRISPR, and small molecule drugs. For more information, visit http://www.entospharma.com.

 ---

Media Contacts:

Montrium

Shima Healey

Marketing Manager, Montrium

marketing@montrium.com

T: +1514 .223. 9153 ext. 283 (North America)

T: +32.2.808.30.08ext. 283 (Europe)

BACK TO NEWS & PUBLICATIONS
Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.